STEFANIA COWSER: Open Payments
NPI 1598477705 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$673 in 33 payments from 14 companies in 2025. Trend: 2023 $181 · 2024 $345 · 2025 $673
Food & beverage: $673
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $105 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| JAZZ PHARMACEUTICALS INC. | 2 | $51 |
| Exact Sciences Corporation | 2 | $48 |
| ABBVIE INC. | 2 | $38 |
| Merck Sharp & Dohme LLC | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $28 |
| SANOFI-AVENTIS U.S. LLC | 1 | $24 |
Products named: REXULTI, Auvelity, XYWAV, BREZTRI, Ozempic, Rybelsus, VRAYLAR, GARDASIL 9.
Industry payments across AL — which companies pay providers there.
